Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ORIC) Institutional Ownership
CUSIP: 68622P109
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
165
Shares (Excl. Options)
119,653,820
Price
$8.18
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- ORIC on Nasdaq
- Shares outstanding
- 97,866,034
- Price per share
- $12.67
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 119,653,820
- Total reported value
- $979,579,552
- % of total 13F portfolios
- 0%
- Share change
- +12,268,927
- Value change
- +$96,243,084
- Number of holders
- 165
- Price from insider filings
- $12.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ORIC - Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 68622P109.
- 165 institutions reported positions in Q4 2025.
- 11 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 165 to 12 between Q4 2025 and Q1 2026.
- Reported value moved from $979,579,552 to $1,453,236.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 165 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 68622P109?
CUSIP 68622P109 identifies ORIC - Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68622P109:
Significant Owners of Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ORIC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 10% | +8.8% | $95,149,860 | +$23,507,430 | 8,729,345 | +33% | VIKING GLOBAL INVESTORS LP | 30 Jun 2025 |
| Nextech Crossover I GP S.a r.l. | 8.4% | $78,072,743 | 7,162,637 | Nextech Crossover I GP S.a. r.l. | 30 Jun 2025 | |||
| EcoR1 Capital, LLC | 6.9% | $73,336,464 | 6,728,116 | EcoR1 Capital, LLC | 29 Jul 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 5.8% | -24% | $57,556,972 | -$9,335,442 | 5,676,230 | -14% | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 |
| BlackRock, Inc. | 5.6% | +35% | $44,773,610 | +$15,158,006 | 5,473,145 | +51% | BlackRock, Inc. | 31 Dec 2025 |
| SR ONE CAPITAL MANAGEMENT, LLC | 4.8% | -13% | $50,307,686 | 4,615,384 | 0% | SR One Capital Management, LLC | 12 Aug 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC | 4.6% | $54,049,152 | 4,504,096 | Alkeon Capital Management LLC | 30 Sep 2025 | |||
| Point72 Asset Management, L.P. | 5.1% | $23,372,809 | 4,401,659 | Point72 Asset Management, L.P. | 29 May 2025 | |||
| COLUMN GROUP II, LP | 3.7% | $48,612,534 | 3,644,118 | Peter Svennilson | 30 Sep 2025 | |||
| FMR LLC | 3.5% | $13,967,797 | 2,467,809 | FMR LLC | 31 Dec 2024 | |||
| Frazier Life Sciences Public Fund, L.P. | 2% | $7,981,692 | 1,410,193 | James N. Topper | 31 Mar 2025 |
As of 31 Dec 2025, 165 institutional investors reported holding 119,653,820 shares of Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ORIC). This represents 122% of the company’s total 97,866,034 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ORIC) together control 94% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Nextech Invest, Ltd. | 7.3% | 7,162,637 | 0% | 5.7% | $58,590,371 |
| EcoR1 Capital, LLC | 6.9% | 6,728,116 | 0% | 2.5% | $55,035,989 |
| VIKING GLOBAL INVESTORS LP | 6.7% | 6,572,691 | -0% | 0.14% | $53,764,612 |
| BlackRock, Inc. | 6% | 5,875,053 | +11% | 0% | $48,057,934 |
| VR ADVISER, LLC | 5.8% | 5,676,230 | -14% | 2.3% | $46,431,561 |
| Pfizer Inc | 5.5% | 5,376,344 | 0% | 19% | $43,978,494 |
| VANGUARD GROUP INC | 4.6% | 4,541,974 | -2.3% | 0% | $37,153,347 |
| SR One Capital Management, LP | 4.6% | 4,514,929 | 0% | 5.3% | $37,753,841 |
| ALKEON CAPITAL MANAGEMENT LLC | 4.6% | 4,504,096 | 0% | 0.16% | $36,843,505 |
| STATE STREET CORP | 4.4% | 4,258,397 | +77% | 0% | $34,833,687 |
| NEA Management Company, LLC | 4.2% | 4,118,621 | 0% | 1.7% | $33,690,320 |
| ORBIMED ADVISORS LLC | 3.7% | 3,641,756 | 0% | 0.64% | $29,789,564 |
| Column Group LLC | 3.6% | 3,540,777 | 0% | 35% | $28,963,556 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.4% | 3,295,122 | +15% | 0% | $26,955,000 |
| Point72 Asset Management, L.P. | 3% | 2,923,077 | +12% | 0.04% | $23,910,770 |
| FMR LLC | 2.5% | 2,478,922 | -1.9% | 0% | $20,277,582 |
| CITADEL ADVISORS LLC | 2.5% | 2,434,710 | +103% | 0.01% | $19,915,928 |
| Paradigm Biocapital Advisors LP | 2.5% | 2,401,217 | 0.53% | $19,641,955 | |
| Vivo Capital, LLC | 2.2% | 2,118,384 | -32% | 1.1% | $17,328,381 |
| First Turn Management, LLC | 2.1% | 2,010,307 | -6.9% | 1.9% | $16,444,311 |
| GOLDMAN SACHS GROUP INC | 2% | 1,939,285 | +114% | 0% | $15,863,351 |
| MPM BIOIMPACT LLC | 1.8% | 1,798,717 | +4% | 1.7% | $14,713,505 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,750,694 | +7.4% | 0% | $14,323,065 |
| ROYCE & ASSOCIATES LP | 1.5% | 1,507,301 | +3.3% | 0.13% | $12,329,722 |
| DIMENSIONAL FUND ADVISORS LP | 1.3% | 1,227,230 | +55% | 0% | $10,037,866 |
Institutional Holders of Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ORIC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 118,216 | $1,453,236 | +$315,808 | $12.67 | 12 |
| 2025 Q4 | 119,653,820 | $979,579,552 | +$96,243,084 | $8.18 | 165 |
| 2025 Q3 | 106,492,104 | $1,277,897,818 | +$159,574,138 | $12.00 | 151 |
| 2025 Q2 | 93,349,298 | $947,499,065 | +$169,716,912 | $10.15 | 140 |
| 2025 Q1 | 79,209,337 | $442,004,992 | +$11,923,513 | $5.58 | 142 |
| 2024 Q4 | 75,794,185 | $611,682,254 | -$16,308,147 | $8.07 | 129 |
| 2024 Q3 | 69,823,199 | $715,076,569 | +$22,655,622 | $10.25 | 121 |
| 2024 Q2 | 67,575,796 | $477,762,911 | +$20,174,043 | $7.07 | 111 |
| 2024 Q1 | 63,945,767 | $879,254,046 | +$197,777,720 | $13.75 | 110 |
| 2023 Q4 | 50,638,764 | $465,880,631 | +$34,655,080 | $9.20 | 91 |
| 2023 Q3 | 48,053,106 | $290,723,321 | +$14,148,790 | $6.05 | 89 |
| 2023 Q2 | 45,537,877 | $353,374,535 | +$99,111,683 | $7.76 | 83 |
| 2023 Q1 | 33,075,099 | $188,527,951 | +$3,515,469 | $5.70 | 70 |
| 2022 Q4 | 32,430,291 | $192,141,081 | +$135,543 | $5.89 | 64 |
| 2022 Q3 | 32,701,288 | $104,643,704 | -$1,866,676 | $3.20 | 69 |
| 2022 Q2 | 32,837,327 | $147,127,000 | -$6,223,365 | $4.48 | 77 |
| 2022 Q1 | 33,856,070 | $180,750,917 | -$7,186,800 | $5.34 | 94 |
| 2021 Q4 | 34,857,324 | $512,119,938 | -$36,775,082 | $14.70 | 79 |
| 2021 Q3 | 31,534,174 | $659,370,855 | +$8,490,366 | $20.91 | 78 |
| 2021 Q2 | 36,145,561 | $639,409,737 | +$2,954,162 | $17.69 | 78 |
| 2021 Q1 | 35,685,685 | $874,284,848 | +$71,774,159 | $24.50 | 82 |
| 2020 Q4 | 32,607,853 | $1,103,814,951 | +$273,075,064 | $33.85 | 76 |
| 2020 Q3 | 22,151,969 | $552,859,000 | +$7,647,968 | $25.01 | 53 |
| 2020 Q2 | 21,388,813 | $718,339,063 | +$718,339,063 | $33.73 | 64 |